MedTrace Logo

Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP

NCT00212030 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2007-11-01

No results posted yet for this study

Summary

To evaluate whether nicorandil as an adjunctive therapy for AMI reduces myocardial infarct size and improves regional wall motion

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

nicorandil

(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion

DRUG

placebo

Control

Sponsors & Collaborators

  • National Cerebral and Cardiovascular Center, Japan

    lead OTHER

Principal Investigators

  • Masafumi Kitakaze, MD, PhD · National Cerebral and Cardiovascular Center, Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2005-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00212030 on ClinicalTrials.gov